Oxolife, a company associated with CataloniaBio  & HealthTech, has launched an international clinical trial to prove the effectiveness of its new treatment to improve the female fertility rate. It is the largest phase II study on female fertility conducted in Spain and it is aimed to improve the implantation of the embryo and increase the success rate of pregnancy, an unmet medical need as there is no therapy to improve embryonic implantation.

The trial has begun thanks to the round of  investment of 5 million euros that Oxolife captured in June 2020, which led Inveready together with the Center for Technological Development Industry (CDTI) and BStartup, among other investors. It has the participation of 24  assisted reproduction clinics in Spain, the Czech Republic and Poland, and plans  to include 351 women undergoing an in vitro fertilization cycle. The study began this September, and the inclusion of patients is expected to be open until February 2022.

Oxolife, the biotechnology company founded in Barcelona in 2013 by Agnès Arbat and Ignasi Canals, is developing OXO-001, a drug that acts specifically on the implantation of the embryo. It is a hormone-free oral tablet that has been shown to be effective in preclinical studies. The current Phase II study is scheduled to be completed in 2023 and, with positive results, the company would lead a final Phase III trial aiming to reach the market with OXO-001 in 2028.

Photo: Agnès Arbat (CEO, CMO) and Ignasi Canals (CSO)